• BRCA2, PARP1 Retention, and RAD51 Filament Protection

  2026-08-12

  The 2025 Nature study identifies PARP inhibitor-induced PARP1 retention on resected DNA as a direct threat to RAD51 filament stability, and shows that full-length BRCA2 prevents this interference. Its biochemical, single-molecule, and cellular evidence clarifies why BRCA2-deficient tumors are especially vulnerable to PARP inhibition and provides a mechanistic framework for DNA repair deficiency targeting.

• Plerixafor (AMD3100) for CXCR4 Research

  2026-08-12

  Plerixafor (AMD3100) provides a reversible way to interrogate CXCL12/CXCR4 signaling in tumor, stem-cell, and immune-cell workflows. This guide translates the reference study’s platelet-extravasation findings into practical assay designs, formulation choices, and troubleshooting strategies.

• ATP Solution (100 mM) for Assay Decision-Making

  2026-08-11

  Discover how ATP Solution supports kinase, transcription, ligation, and phosphorylation workflows while avoiding overinterpretation of assay results. This guide connects ATP chemistry with practical quality controls and the p21 mRNA-LNP bladder cancer study.

• Hexa-Acylated LPS and Cancer Immunotherapy

  2026-08-11

  A Nature Microbiology study identifies the structure of gut microbiota-derived lipopolysaccharide (LPS), rather than bacterial taxonomy alone, as a functional determinant of anti-PD-1 response. Using human metagenomics, cellular assays, and mouse tumor models, the authors show that hexa-acylated LPS activates TLR4-dependent immunity and can enhance checkpoint inhibitor efficacy.

• Aurora A, SAM Metabolism, and Trained Immunity

  2026-08-10

  Li et al. identify Aurora kinase A as a regulator of β-glucan-trained immunity that connects mTOR–FOXO3–GNMT signaling with endogenous S-adenosylmethionine availability and histone methylation. Their integrated chromatin, transcriptomic, metabolomic, cellular, and animal experiments show that AurA inhibition weakens inflammatory recall and removes the tumor-suppressive effect of trained immunity in mice.

• BMN 673: PARP Trapping in DNA Repair Studies

  2026-08-09

  BMN 673 (Talazoparib) combines exceptionally potent PARP1/2 inhibition with strong PARP-DNA complex trapping, making it a useful probe for DNA repair deficiency and synthetic-lethality experiments. This guide translates spliceosome-focused hepatocellular carcinoma findings into practical viability, mechanistic, combination, and troubleshooting workflows.

• Streptavidin-Cy3 for NPC Metastasis Assays

  2026-08-08

  Streptavidin-Cy3 converts biotinylated antibodies and nucleic-acid probes into bright, spatially resolved readouts for nasopharyngeal carcinoma research. This guide connects the seRNA-NPCm mechanism to practical IHC, IF, ISH, and flow cytometry workflows while emphasizing controls, titration, and troubleshooting.

• Neomycin sulfate in Reliable Cell Assays

  2026-08-07

  Learn how Neomycin sulfate (SKU B1795) can be used as a defined mechanistic perturbant in cell viability, proliferation, and cytotoxicity workflows. This scenario-based guide addresses solvent compatibility, storage, assay interpretation, and vendor-selection decisions without treating the antibiotic as a universally neutral control.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-08-07

  Schwartz's dissertation advances in vitro methods for distinguishing drug-induced growth inhibition from cell death, highlighting the importance of separate viability metrics in preclinical cancer research. These innovations inform more precise evaluation of agents like novel PARP inhibitors, optimizing the translation of laboratory findings into clinical insights.

• AZD0156: ATM Kinase Inhibitor Workflows for Cancer Research

  2026-08-06

  AZD0156, a highly selective ATM kinase inhibitor, enables precise modulation of DNA damage response pathways and metabolic vulnerabilities in cancer therapy research. This article delivers actionable workflows, troubleshooting guidance, and advanced use-cases—grounded in recent high-impact findings—to empower translational teams targeting HR-proficient malignancies.

• 5-Aminolevulinic acid HCl: Reliable Solutions for Heme Biosy

  2026-08-06

  This article explores practical laboratory challenges in cell viability and host-pathogen research, demonstrating how 5-Aminolevulinic acid HCl (SKU B2070) from APExBIO delivers reproducible, data-backed solutions. Emphasis is placed on optimizing experimental design, protocol reliability, and product selection for workflows centered on heme biosynthesis and immune evasion.

• Phosbind Acrylamide: Precision Phosphorylation Analysis with

  2026-08-05

  Phos binding reagent (Phosbind) acrylamide unlocks high-resolution, antibody-free phosphorylation state analysis for proteins in the 30–130 kDa range. This workflow guide details experimental optimizations, advanced applications, and troubleshooting insights, empowering researchers to streamline SDS-PAGE phosphorylation detection and signal transduction studies.

• Bafilomycin A1: Precision V-ATPase Inhibitor for Lysosomal A

  2026-08-05

  Bafilomycin A1 enables researchers to dissect lysosomal function and autophagy dynamics with nanomolar precision. This article details optimized workflows, troubleshooting strategies, and translational insights for deploying Bafilomycin A1 in advanced cell biology, with actionable takeaways drawn from cutting-edge literature.

• AZD1390 and the ATM Pathway: Precision Radiosensitization De

  2026-08-04

  Explore the molecular precision of AZD1390, a leading ATM kinase inhibitor, in radiosensitizing glioma and lung cancer. This article uniquely connects ATM pathway modulation to emerging G-quadruplex DNA insights, offering researchers practical guidance beyond standard protocols.

• Selective Human ClpP Activation Induces Cell Cycle Arrest in

  2026-08-04

  The referenced study identifies ZK53 as a highly selective activator of the human mitochondrial serine protease ClpP, demonstrating potent inhibition of lung squamous cell carcinoma (LUSC) by disrupting mitochondrial bioenergetics. This work establishes a mechanistic link between targeted ClpP activation, mitochondrial dysfunction, and cell cycle arrest, offering a precise tool for dissecting mitochondrial proteostasis in cancer research.

11576 records 1/772 page Next 12345 下5页 Last page